Multiscale modeling of tumor response to vascular endothelial growth factor (VEGF) inhibitor

Vascular endothelial growth factor (VEGF) has been known as a key mediator of angiogenesis in cancer. Bevacizumab is anti-VEGF monoclonal antibody that has been approved by the FDA as a first-line treatment in many types of cancer. In this paper, we extend a previously validated multiscale tumor mod...

Descripción completa

Detalles Bibliográficos
Autores principales: Hendrata, Melisa, Sudiono, Janti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842763/
https://www.ncbi.nlm.nih.gov/pubmed/35001886
http://dx.doi.org/10.3233/ISB-210235

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842763/
https://www.ncbi.nlm.nih.gov/pubmed/35001886
http://dx.doi.org/10.3233/ISB-210235

Ejemplares similares